NCT05288166 2025-06-27CYCLONE 3Eli Lilly and CompanyPhase 3 Active not recruiting925 enrolled 12 charts
NCT03878524 2024-03-04Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialOHSU Knight Cancer InstitutePhase 1 Terminated2 enrolled
NCT04087174 2022-07-13A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate CancerAstraZenecaPhase 1 Completed27 enrolled
NCT01741753 2019-02-05BKM120+Abiraterone Acetate for Metastatic CRPCDana-Farber Cancer InstitutePhase 1 Terminated4 enrolled